1459754-32-5

Basic information

• Product Name: 4-(2-chloro-5-iodobenzyl)phenol
• Synonyms: 4-(2-chloro-5-iodobenzyl)phenol;4-[(5-IODo-2-chlorophenyl)methyl]Phenol
• CAS NO: 1459754-32-5
• Molecular Formula: C₁₃H₁₀ClIO
• Molecular Weight: 344.57537
• EINECS: -0
• Mol File: 1459754-32-5.mol

Chemical Properties

• Boiling Point: 420.2±40.0 °C(Predicted)
• Appearance: /
• Density: 1.711±0.06 g/cm3(Predicted)
• PKA: 10.14±0.15(Predicted)
• CAS DataBase Reference: 4-(2-chloro-5-iodobenzyl)phenol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-chloro-5-iodobenzyl)phenol(1459754-32-5)
• EPA Substance Registry System: 4-(2-chloro-5-iodobenzyl)phenol(1459754-32-5)

Safety Data

• Hazardous Substances Data: 1459754-32-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(2-chloro-5-iodobenzyl)phenol is used as a key intermediate in the production of drugs, leveraging its chemical properties to contribute to the development of novel therapeutic agents.
Used in Academic Research:
In the field of academic research, 4-(2-chloro-5-iodobenzyl)phenol serves as a valuable tool for studying the structure-activity relationships of different compounds, aiding in the understanding of how molecular modifications can influence biological activity.
Used in Medicinal Chemistry:
4-(2-chloro-5-iodobenzyl)phenol is utilized in medicinal chemistry for its potential applications in drug discovery, where its unique structure and reactivity can be harnessed to create new compounds with desired pharmacological properties.
Used in Drug Synthesis:
4-(2-chloro-5-iodobenzyl)phenol is employed as a building block in the synthesis of various biologically active compounds, playing a crucial role in the development of new drugs with improved efficacy and selectivity.

Upstream product

• 1459754-40-5 (2-chloro-5-iodophenyl)(4-hydroxyphenyl)methanone 
• 103-73-1 Phenetole 
• 100-66-3 methoxybenzene 
• 1459754-39-2 (2-chloro-5-iodophenyl)(4-methoxyphenyl)methanone 
• 1459754-36-9 2-(4-methoxybenzyl)-1-chloro-4-iodobenzene 
• 108-95-2 phenol 
• 19094-56-5 2-chloro-5-iodobenzoic acid 
• 281652-58-2 2-chloro-5-iodobenzoylchloride 

Downstream Products

• 1400980-44-0 1-chloro-2-(4-(2-cyclopropoxyethoxy)benzyl)-4-iodobenzene 
• 864070-44-0 empagliflozin 
• 864070-37-1 (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-hydroxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 1204220-63-2 (2S,3R,4S,5S,6R)-2-(4-chloro-3-(4-hydroxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol 
• 915095-94-2 (3S)-3-[4-[(2-chloro-5-iodophenyl)methyl]phenoxy]tetrahydrofuran 
• 912917-83-0 (3R,4S,5S,6R)-2-(4-chloro-3-(4-hydroxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol 

Relevant articles and documents

Empagliflozin intermediate preparation method

The invention discloses an empagliflozin intermediate preparation method, which comprises: carrying out substitution by using p-methoxybenzyl chloride and p-iodoaniline as starting raw materials to obtain a compound IV, performing diazotization and a Sandmeyer reaction to obtain a compound III, further performing demethylation under the action of boron tribromide to obtain a compound II, and finally performing condensation with (S)-3-p-toluenesulfonyloxy tetrahydrofuran to obtain the target compound I, wherein the product purity is greater than or equal to 99.0%. According to the invention, the preparation method has advantages of simple and easily available raw materials, low cost, simple operation steps, simple post-treatment and high product yield, and is suitable for industrial production.

Design, synthesis and anticancer activities of halogenated Phenstatin analogs as microtubule destabilizing agent

A series of halogenated Phenstatin analogs were designed as microtubule destabilizing agent by docking study. It was synthesized within three steps starting from 2-chloro-5-iodobenzoic acid and substituted benzene. All the products were characterized by 1H NMR and 13C NMR spectral analysis, and the stereochemical structure was also confirmed by a single crystal X-ray diffraction crystallographic analysis. The microtubule destabilizing activities were evaluated in vitro with human liver cancer Huh-7 cell line and human lung cancer A549 cell line. Some of the HPAs were achieved IC50 about 5.0 μM against human liver cancer Huh-7 cells. [Figure not available: see fulltext.].

Synthetic method for empagliflozin related substance IMPD

The invention discloses a synthetic method for empagliflozin related substance IMPD. In a current synthetic method of IMPD, a whole synthetic route is longer and the total yield is lower. The synthetic method provided by the invention comprises the following steps: performing hydroxylation by using (2-chloro-5-iodophenyl)(4-fluorophenyl)methanone as a raw material to obtain (2-chloro-5-iodophenyl)(4-hydroxyphenyl)methanone, performing a reaction by using a carbonyl reducing agent to obtain 4-(5-iodo-2-chlorobenzyl)phenol, protecting phenolic hydroxyl groups by using protecting groups such as TBDMS, performing metallization of aromatic iodide by adopting a relatively stable and safe Grignard reagent i-PrMgCl.LiCl, performing methyl glucoside reduction by using a Lewis acid catalyst, and finally performing quenching to obtain the empagliflozin related substance IMPD. The synthetic method provided by the invention has the advantages of an abundant raw material source, a simple, quick andhigh-efficiency reaction, milder reaction conditions, a higher total yield and low costs.

SOLID STATE FORMS OF EMPAGLIFLOZIN

The present invention provides solid state forms of empagliflozin, complexes of empagliflozin with amino acids, processes for their preparation and their use in purification of empagliflozin and also provided pharmaceutical compositions comprising them and their use in therapy (Formula I).

PREPARATION OF HYDROXY-BENZYLBENZENE DERIVATIVES

Methods for preparing intermediates of SGLT2 inhibitors are provided, including crystalline forms and methods of crystallizing intermediates.

PREPARATION OF HYDROXY-BENZYLBENZENE DERIVATIVES

Methods for preparing intermediates of SGLT2 inhibitors are provided, including crystalline forms and methods of crystallizing intermediates.

PREPARATION OF HYDROXY-BENZYLBENZENE DERIVATIVES

Methods for preparing intermediates of SGLT2 inhibitors are provided, including crystalline forms and methods of crystallizing intermediates.

OPTICALLY PURE BENZYL-4-CHLOROPHENYL-C-GLUCOSIDE DERIVATIVE

The present invention belongs to the field of pharmaceutical technology, more specifically relates to optically pure benzyl-4-chlorophenyl-C-glucoside derivatives represented by formulae (II) and (III), a process for preparing these compounds and intermediates thereof, a pharmaceutical formulation and a pharmaceutical composition containing these compounds, and the use of the optically pure benzyl-4-chlorophenyl-C-glucoside derivative as a sodium glucose co-transporter (SGLT) inhibitor in manufacture of a medicament for treating and/or preventing diabetes mellitus (including insulin-dependent diabetes mellitus and non-insulin-dependent diabetes mellitus) or diabetes-associated diseases (including insulin resistance disease and obesity)

OPTICALLY PURE BENZYL-4-CHLOROPHENYL-C-GLUCOSIDE DERIVATIVE

The present invention relates to a pharmaceutical technology, and more specifically, to optically pure benzyl-4-chloro-phenyl glucoside derivatives represented by the chemical formula II and III or a pharmaceutically acceptable salt thereof. The present invention also relates to a method for preparing the compounds and intermediates thereof, pharmaceutical formulations and pharmaceutical compositions containing the compounds, and the use of the optically pure benzyl-4-chloro-phenyl glucoside derivatives as sodium glucose co-transporter (SGLT) inhibitors for the prevention and treatment of the diabetes including the insulin dependent diabetes mellitus and non-insulin dependent diabetes mellitus and the diabetes-related deseases such as insulin-resistant diseases and obesity.COPYRIGHT KIPO 2015

Optically pure benzyl-4-chlorophenyl-C-glucoside derivatives as SGLT inhibitors (diabetes mellitus)

The present invention belongs to the field of pharmaceutical technology, more specifically relates to optically pure benzyl-4-chlorophenyl-C-glucoside derivatives represented by formulae (II) and (III), a process for preparing these compounds and intermediates thereof, a pharmaceutical formulation and a pharmaceutical composition containing these compounds, and the use of the optically pure benzyl-4-chlorophenyl-C-glucoside derivative as a sodium glucose co-transporter (SGLT) inhibitor in manufacture of a medicament for treating and/or preventing diabetes mellitus (including insulin-dependent diabetes mellitus and non-insulin-dependent diabetes mellitus) or diabetes-associated diseases (including insulin resistance disease and obesity) or